Latest Mergers And Acquisitions News

Imugene Limited has completed a $22.5 million institutional placement and launched a $15 million Share Purchase Plan, both featuring attaching options, to fund its azer-cel clinical program through a pivotal trial in 2026.

The Federal Court has approved Yumbah Aquaculture’s acquisition of Clean Seas Seafood, setting the stage for a significant consolidation in Australia’s seafood farming sector. Shareholders face a choice between cash or shares as the scheme moves toward implementation.

Caspin Resources has completed the second tranche of its $2.1 million capital raising, issuing shares and free-attaching options approved by shareholders. The move strengthens funding for its diverse Australian mineral projects.

Hawsons Iron Limited has successfully raised $1.91 million through an oversubscribed Share Purchase Plan and a targeted Placement, positioning the company to fast-track key project studies and environmental assessments.

ImpediMed has doubled its US unit sales in Q4 FY25, achieving a record total contract value and securing an additional $5 million tranche under its growth capital facility.

Lord Resources has successfully raised $1.39 million through a shortfall placement, setting the stage for imminent drilling at its high-grade Ilgarari Copper Project in Western Australia.

DigitalX Limited reports a $75.6 million treasury valuation driven by Bitcoin and digital assets, completing a $20.7 million capital raise to expand its Bitcoin-first strategy.

Bryah Resources has exercised its option to acquire the Golden Pike Project in New Brunswick, revealing significant high-grade antimony and gold mineralisation potential supported by historical data and recent drilling.

Scalare Partners Holdings has voluntarily suspended trading on the ASX as it prepares to announce a capital raising tied to its planned acquisition of Tank Stream Labs.

Alliance Nickel has strengthened its financial position with an additional A$1.2 million unsecured loan and extended existing facilities, while reaffirming the commercial viability of its NiWest Nickel-Cobalt Project through a comprehensive Definitive Feasibility Study.

Prescient Therapeutics has initiated its first US clinical site for the PTX-100 Phase 2a trial targeting Cutaneous T-Cell Lymphoma, marking a key milestone in expanding patient recruitment beyond Australia.

Vection Technologies has secured a $0.5 million extension order from a new department within an existing Defence customer, opening doors to a $27 million budget pipeline over three years.